ArticleIndian journal of surgical oncology2025
Peritumoral CD117 Immunopositive Mast Cell Density in Prostatic Adenocarcinoma and Its Correlation with the New Gleason Score.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD117 immunopositive mast cells play an important role in prostate cancer tumorigenesis. Most of the trials on the use of imatinib in prostate cancer have relied on the anti-PDGFR (anti-platelet-derived growth factor receptor) activity of imatinib. The CD117 immunohistochemistry on intratumoral and peritumoral mast cells was performed using the archival blocks of 40 patients with prostatic adenocarcinoma. The mast cells within and at the periphery of the tumor were counted in three areas with the highest mast cell density chosen by scanning the entire specimen section at low magnification, first on hematoxylin and eosin and then on the immunohistochemistry slide. The mean mast cell counts per high power field (× 40) were calculated by taking the mean of 10 high power fields. Then, the mean mast cell count of the case was calculated by taking the mean of all the tissue blocks of the case. The samples were graded histopathologically using the new Gleason scoring system (WHO 2016). The Kruskal-Wallis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.